Dr. Neetu Talreja, MD

Dr. Talreja practices at Allergy Group in Boise, Idaho.

Dr. Talreja's NPI, 1326206889, was assigned on May 30, 2008. Dr. Talreja graduated from Kasturba Medical College Manipal in 2004. Dr. Talreja holds Idaho license M12227.

Dr. Talreja's primary practice is Allergy Group, at 1000 N Curtis Rd Suite 303 Suite 303, Boise, ID 83706-1347. The practice phone is (208) 377-4000.

Dr. Talreja's primary practice is Allergy Group in Boise, Idaho. Dr. Talreja is also affiliated with St. Luke's Boise Medical Center. The medical group on file is The Allergy Group. Dmand AI also links Dr. Talreja to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Talreja practices, 3 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Talreja's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Talreja is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Talreja's licenses on file in 6 states: Idaho, Florida, Kansas, Michigan, Colorado and Pennsylvania.

Dmand AI lists acute sinusitis, asthma, chronic nasal allergies, chronic sinusitis, hives and immune deficiency disease among the conditions Dr. Talreja treats.

CMS data shows 6,657 Medicare services from Dr. Talreja across 8 procedure codes in 2024, for 164 Medicare patients. Medicare paid $53,565 for them. Every service was in an office.

CMS counts 164 Medicare patients who saw Dr. Talreja in 2024. The largest group is 65 to 74, with 97 patients. 62% of them have high cholesterol, and 49% have high blood pressure. 9% are also on Medicaid. Their average risk score is 0.81, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Talreja's median patient age at 43, with 61% women.

In 2024, Dr. Talreja wrote 635 Medicare Part D claims for 142 patients. 65% of them were for generic drugs. CMS names the drug for 555 of them, across 17 drugs with 11 or more claims each, at $111,870 in total drug cost. In 2023, CMS named 512 claims across 15 drugs.

Dr. Talreja accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Talreja, published from 2010 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Asthma. Dr. Talreja has published most often in Ann Allergy Asthma Immunol. Dr. Talreja's most frequent co-authors are Richard F. Lockey, MD, John Talyor Anderson, MD and Jonathan A. Bernstein, MD.

Dmand AI links Dr. Talreja to 1 clinical trial. Conditions studied include Chronic Urticaria and Urticaria. Open Payments lists research payments to Dr. Talreja that name 2 trials.

CMS Open Payments shows 368 general payments to Dr. Talreja from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 41% of the total. ARS Pharmaceuticals Operations, Inc. paid the most, $4,702. It also lists 6 research payments totaling $46,497 from 2020 to 2024, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Talreja, most recently Member in 2014.

Dr. Talreja graduated from Kasturba Medical College Manipal in 2004. Dr. Talreja is a member of AAAAI, American College of Allergy Asthma and Immunology- ACAAI and AMA.

Dr. Talreja is in network with 20 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.